Protocol Ledger

NCT06201234 · Phase II · RECRUITING

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Interventional Phase II clinical trial protocol NCT06201234 sponsored by GBG Forschungs in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-13 Enrollment: 176 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06201234
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)176 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06201234
Protocol FieldVerified Registry Value
NCT IdentifierNCT06201234
Consolidated Lead SponsorGBG Forschungs
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment176 participants (ESTIMATED)
Registered Start Date2024-12-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06201234
Hospital Research SiteLocationSite Profile
Medizinische Hochschule HannoverHanover, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI